Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2055-0294
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database ; volume:5 ; number:1 ; day:7 ; month:10 ; year:2019 ; pages:1-4 ; date:12.2019
Journal of pharmaceutical health care and sciences ; 5, Heft 1 (7.10.2019), 1-4, 12.2019
- Urheber
-
Niinomi, Iku
Hosohata, Keiko
Mori, Yasuhiro
Yamaguchi, Yuki
Wakabayashi, Tomohito
Uchida, Mayako
Iwanaga, Kazunori
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40780-019-0149-z
- URN
-
urn:nbn:de:101:1-2020020819535181780345
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Niinomi, Iku
- Hosohata, Keiko
- Mori, Yasuhiro
- Yamaguchi, Yuki
- Wakabayashi, Tomohito
- Uchida, Mayako
- Iwanaga, Kazunori
- SpringerLink (Online service)
Ähnliche Objekte (12)
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis